While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Merck‘s performance in 2025 started rough due to weaker-than-expected results, despite surpassing Wall Street estimates with ...